Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$ 5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials NASDAQ:NGEN) after the company said it had completed its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, clearing the way for the Phase 3 RESTORE trial in chronic tetraplegia. Uddin […]
In an April 8 note, Paradigm Capital analyst Scott McAuley maintained his “Speculative Buy” rating on Perimeter Medical Imaging AI (Perimeter Medical Imaging AI Stock Quote, Chart, News, Analysts, Financials TSXV:PINK) and raised his target to C$0.95 from C$0.70 after fourth-quarter results and recent M&A activity in breast cancer surgery. McAuley said Perimeter’s FDA-cleared Claire device […]
Share
Tweet
Share
